:: Library Catalog

Imagen de Portada

Guardado en:

Detalles Bibliográficos
Autores principales:	Juan Macias, Mario Frias, Juan Antonio Pineda, Diana Corona‐Mata, Anais Corma‐Gomez, Antonio Rivero‐Juarez, Marta Santos, Miguel García‐Deltoro, Antonio Rivero, Carmen Ricart‐Olmos, Alejandro Gonzalez‐Serna, Luis Miguel Real
Formato:	Artículo Open Access
Publicado:	Wiley 2024
Materias:	Alimentary Pharmacology & Therapeutics
Acceso en línea:	https://onlinelibrary.wiley.com/doi/10.1111/apt.18413
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Letter: Impact of Nonalcoholic Fatty Liver Disease on the Survival of People Living With HIV—Authors' Reply
por: Juan Macias, et al.
Publicado: (2025)

Letter: Impact of Nonalcoholic Fatty Liver Disease on the Survival of People Living With HIV
por: Rong‐Xiang Ng, et al.
Publicado: (2025)

Systematic Review: Incidence of Liver‐Related Events in People Living With Hepatitis Delta Virus
por: Laura E. Telep, et al.
Publicado: (2025)

Letter on ‘Inherited Genetic Risk of Liver Fibrosis in Lean Versus Nonlean Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD )’; Authors’ reply
por: Kaleb Tesfai, et al.
Publicado: (2026)

Letter: Safety and Tolerability of Injectable Extended‐Release Naltrexone for the Management of Alcohol Use Disorder in Advanced Alcohol‐Associated Liver Disease—Authors' Reply
por: Luis Antonio Díaz, et al.
Publicado: (2025)

Editorial: Comparable Hepatic Fibrosis Risk Demands Equal Vigilance in Lean and Non‐Lean Patients With Metabolic Dysfunction‐Associated Steatotic Liver Disease—Authors' Reply
por: Kaleb Tesfai, et al.
Publicado: (2025)

Safety and Tolerability of Injectable Extended‐Release Naltrexone for the Management of Alcohol Use Disorder in Advanced Alcohol‐Associated Liver Disease
por: Luis Antonio Díaz, et al.
Publicado: (2025)

Subtype Differences in Major Adverse Liver Outcomes and Cardiovascular Events and Mortality in Steatotic Liver Disease: A UK Biobank Analysis
por: Takao Miwa, et al.
Publicado: (2026)

Letter: Predictors of Corticosteroid Response in Alcohol‐Related Hepatitis—Authors' Reply
por: Francisco Idalsoaga, et al.
Publicado: (2025)

Differential Characteristics and Survival Outcomes of Patients With Cirrhosis According to Underlying Liver Aetiology
por: Yu Shi, et al.
Publicado: (2025)

Letter: Refining Mortality Estimates in Severe Alcohol–Associated Hepatitis—Addressing Heterogeneity and Prognostic Assessment. Authors' Reply
por: Francisco Idalsoaga, et al.
Publicado: (2025)

Letter on ‘Meta‐Analysis: Mortality Trends and Risk Factors in Severe Alcohol‐Associated Hepatitis’—Authors' Reply
por: Francisco Idalsoaga, et al.
Publicado: (2025)

Editorial: Effectiveness and safety of ustekinumab in ulcerative colitis—Where we are now in real life
por: Giammarco Mocci, et al.
Publicado: (2024)

The Prevalence and Risk Factors for at‐Risk MASH and Advanced Liver Fibrosis in People With Metabolic Risk Factors in Primary Care
por: Leon A. Adams, et al.
Publicado: (2026)

Editorial: Patient Reported Outcomes Provide Insight Into Disease Severity for People Living With Primary Sclerosing Cholangitis
por: Aisha Alawi, et al.
Publicado: (2025)

Effect of Nucleos(t)ide Analogues Withdrawal on Survival Outcomes in Patients With Hepatitis B Virus‐Related Acute‐on‐Chronic Liver Failure
por: Yanxue Lin, et al.
Publicado: (2025)

Editorial: Metabolic Dysfunction and Alcohol—Two Sides of the Same Coin
por: Gustavo Ayares, et al.
Publicado: (2024)

Editorial: Liver and Non‐Liver Outcomes Between Different Subtypes of Steatotic Liver Disease
por: Jee‐Fu Huang, et al.
Publicado: (2026)

Surviving Hepatitis C—Understanding Death and Survival Beyond Cure
por: Paul J. Clark, et al.
Publicado: (2025)

Letter: Potential impact ofHelicobacter pyloriinfection on oesophageal disorders in chronic liver disease—Authors' reply
por: Francisco Idalsoaga, et al.
Publicado: (2024)

Review article: Oesophageal disorders in chronic liver disease
por: Francisco Idalsoaga, et al.
Publicado: (2024)

Letter: Increased Prevalence of Visceral Obesity in Nonresponder Patients With Primary Biliary Cholangitis Based on Computed Tomography—Authors' Reply
por: Conrado Fernandez‐Rodriguez, et al.
Publicado: (2024)

Editorial: The Hidden Burden—Stigmatisation in Inflammatory Bowel Disease
por: Marco Vincenzo Lenti, et al.
Publicado: (2025)

Assessing Major Adverse Liver Outcomes With Baclofen Compared to Acamprosate in Compensated Alcohol‐Associated Cirrhosis
por: Yee Hui Yeo, et al.
Publicado: (2026)

Letter: The multifaceted role of Escherichia coli in influencing disorders of industrial populations
por: Maria Rosa Ingrosso, et al.
Publicado: (2024)

Alcohol–Related Liver Disease, Followed by Metabolic Dysfunction–Associated Steatotic Liver Disease, Emerges as the Fastest‐Growing Aetiologies for Primary Liver Cancer in the United States
por: Pojsakorn Danpanichkul, et al.
Publicado: (2025)

Meta‐Analysis: Mortality Trends and Risk Factors in Severe Alcohol‐Associated Hepatitis
por: Mushfiqur R. Siddique, et al.
Publicado: (2025)

Diagnostic Impact of Liver Biopsy Among Antinuclear Antibody Positive Individuals With Mild Liver Enzyme Elevation
por: David Mehdi Asgher Niazi, et al.
Publicado: (2026)

Editorial: Steatotic Liver Diseases Emerge as Rapidly Growing Drivers of Primary Liver Cancer in the United States
por: Kelly Torosian, et al.
Publicado: (2025)

Waitlist and Post‐Transplant Outcomes in Liver Transplantation for Alcohol‐Associated Liver Disease: An Individual Patient Data Meta‐Analysis
por: Glenn Jun Kit Ho, et al.
Publicado: (2025)

Editorial: Balancing the Yin and Yang of Alcohol‐Associated Liver Disease—Integrating Pathophysiology, Liver‐Directed Therapy and Addiction Management
por: Raj Vuppalanchi, et al.
Publicado: (2025)

Predicting Hepatic Decompensation in Patients With Metabolic Dysfunction Associated Steatotic Liver Disease‐Related Cirrhosis: The ABID‐LSM Model
por: Luis Calzadilla Bertot, et al.
Publicado: (2025)

Hepatic Events During Immune Checkpoint Inhibitor Treatment Between Liver and Non‐Liver Malignancies in Hepatitis B Endemic Areas
por: Yi‐Ping Hung, et al.
Publicado: (2024)

Letter: Liver Transplantation Outcomes for Alcohol‐Associated Liver Disease—Commentary on an Individual Patient Data Meta‐Analysis and Future Research Directions
por: Xinglin Li, et al.
Publicado: (2026)

Editorial: The Role of Liver Biopsy in ANA Positive Subjects
por: Einar S. Björnsson
Publicado: (2026)

Editorial: Revolutionising Steatotic Liver Disease Diagnosis With Phosphatidylethanol
por: Karen Cheuk‐Ying Ho, et al.
Publicado: (2025)

Editorial: Cephalosporin‐Induced Liver Injury—Interesting but Tricky
por: Einar S. Björnsson
Publicado: (2025)

The Emerging Short Chain Fatty Acid Enriched Metabotype in Irritable Bowel Syndrome and Its Potential Clinical Relevance
por: T. E. Conley, et al.
Publicado: (2026)

Letter: Global Burden of Metabolic Dysfunction‐Associated Steatotic Liver Disease‐Related Liver Cancer—Results From the Global Burden of Disease Study 2021
por: Chunlong Liu, et al.
Publicado: (2025)

Letter: Liver Transplantation Outcomes for Alcohol‐Associated Liver Disease—Commentary on an Individual Patient Data Meta‐Analysis and Future Research Directions. Authors' Reply
por: Ryan Yanzhe Lim, et al.
Publicado: (2026)